Epithelial and epidermal cytokines (e.g., IL-25, IL-33, and thymic stromal lymphopoietin [TSLP]) released in AD skin lesions can further stimulate group 2 innate lymphoid cells (ILC2) to release type 2 cytokines (e.g., IL-5 and IL-13) [33, 34]. This evidence concerns the gene IL25 and Alzheimer disease.